Hybrigenics

Biopharmaceutical company Hybrigenics, based in Paris, has signed a contract as part of the European Union research project Masterswitch. The company will receive more than €400,000 over the first two years of the five-year agreement, which will enable it to develop a high-throughput assay and attempt to identify small-molecule inhibitors of a protein reaction found in chronic inflammatory diseases.





LATEST NEWS

• Exail Signs LLNL Contract, Partners with Eelume
  Apr 26, 2024
• Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
  Apr 26, 2024
• Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
  Apr 25, 2024
• DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
  Apr 25, 2024
• Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
  Apr 24, 2024
• One-Step Hologram Generation Speeds 3D Display Creation
  Apr 24, 2024
• Innovation Award Winners for Laser Technology Honored in Aachen
  Apr 23, 2024
• Intech 2024: AI Arrives on the Shop Floor
  Apr 22, 2024